

1 ***NCOA3* identified as a new candidate to explain autosomal dominant progressive**
2 **hearing loss**

3
4 Rodrigo Salazar da Silva¹, Vitor Lima Goes Dantas¹, Leandro Ucela Alves¹, Ana Carla
5 Batissoco^{1,2}, Jeanne Oiticica², Elizabeth A Lawrence³, Abdelwahab Kawafi³, Yushi
6 Yang^{4,5,6}, Fernanda Stávale Nicastro⁷, Beatriz Caiuby Novaes⁷, Chrissy Hammond³,
7 Erika Kague^{1,3*#} and Regina Célia Mingroni Netto^{1*#}

8
9 1. Centro de Pesquisas sobre o Genoma Humano e Células-Tronco, Departamento de
10 Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo,
11 05508-090, São Paulo, Brazil

12 2. Laboratório de Otorrinolaringologia/LIM32 – Hospital das Clínicas, Faculdade de
13 Medicina, Universidade de São Paulo, 01246-903, São Paulo, Brazil

14 3. School of Pharmacology, Physiology and Neuroscience, University of Bristol,
15 Bristol, BS8 1TD, United Kingdom.

16
17 4. School of Physics, University of Bristol, Bristol, BS8 1TL, United Kingdom.

18
19 5. Centre for Nanoscience and Quantum Information, University of Bristol, Bristol, BS8
20 1FD, United Kingdom.

21
22 6. Bristol Centre for Functional Nanomaterials, University of Bristol, Bristol, BS8 1FD,
23 United Kingdom.

24
25 7. Divisão de Educação e Reabilitação dos Distúrbios da Comunicação da Pontifícia
26 Universidade Católica de São Paulo, 04022-040, São Paulo, Brazil

27

28

29 * Corresponding authors:

30 Regina Célia Mingroni Netto (renetto@ib.usp.br) and Erika Kague
31 (erika.kague@bristol.ac.uk)

32

33 # joint senior authors

34

35

36

37 **Abstract**

38

39 Hearing loss is a frequent sensory impairment in humans and genetic factors account for
40 an elevated fraction of the cases. We have investigated a large family of five
41 generations, with 15 reported individuals presenting non-syndromic, sensorineural,
42 bilateral and progressive hearing loss, segregating as an autosomal dominant condition.
43 Linkage analysis, using SNP-array and selected microsatellites, identified a region of
44 13cM in chromosome 20 as the best candidate to harbour the causative mutation. After
45 exome sequencing and filtering of variants, only one predicted deleterious variant in the
46 *NCOA3* gene (NM_181659, c.2810C>G; p.Ser937Cys) fit in with our linkage data. RT-
47 PCR, immunostaining and *in situ* hybridization showed expression of *ncoa3* in the inner
48 ear of mice and zebrafish. We generated a stable homozygous zebrafish mutant line
49 using the CRISPR/Cas9 system. *ncoa3*^{-/-} did not display any major morphological
50 abnormalities in the ear, however, anterior macular hair cells showed altered orientation.
51 Surprisingly, chondrocytes forming the ear cartilage showed abnormal behaviour in
52 *ncoa3*^{-/-}, detaching from their location, invading the ear canal and blocking the cristae.
53 Adult mutants displayed accumulation of denser material wrapping the otoliths of
54 *ncoa3*^{-/-} and increased bone mineral density. Altered zebrafish swimming behaviour
55 corroborates a potential role of *ncoa3* in hearing loss. In conclusion, we identified a
56 potential candidate gene to explain hereditary hearing loss, and our functional analyses
57 suggest subtle and abnormal skeletal behaviour as mechanisms involved in the
58 pathogenesis of progressive sensory function impairment.

59 **Introduction**

60 Hearing loss affects almost 466 million people worldwide and is estimated to
61 affect more than 900 million people by 2050 (1). Genetic factors play an important role
62 in the pathogenesis of the disease, with up to 55% of age-related hearing loss attributed
63 to genetics (2). Approximately 70% of hereditary deafness cases are non-syndromic (3),
64 of which 20% are autosomal dominant (2). Autosomal dominant non-syndromic hearing
65 loss (ADNSHL) is typically progressive with late and variable average age of onset,
66 which depends on the nature of the type of mutation and affected gene.

67 Mapping studies of large families have contributed to the identification of
68 several genes associated with hearing loss (4). Recently, whole-genome and exome
69 sequencing, in combination with familial cases, have boosted the identification of causal
70 genes (4–8). The genetic complexity of the condition is highlighted by the large number
71 of genes identified as associated to monogenic inheritance of non-syndromic hearing
72 loss (~130), and those related to ADNSHL (~50) (9). New genes are still to be
73 identified, however, given the extensive genetic heterogeneity underpinning the origin
74 of hearing loss, newly identified genes and variants are rarely found, in only one or a
75 few pedigrees, making their confirmation by reproducibility a challenging task.
76 Therefore, functional studies are key to validate the genetic findings.

77 Hearing loss associated genes fall into common categories such as maintenance
78 of ionic homeostasis, formation of hair cell stereocilia and regulation of gene
79 transcription (10–15). Recently, other pathways have also been suggested to play a role
80 in disease pathogenesis; such as collagen biogenesis and homeostasis (16–18). Thus, the
81 identification of novel candidate genes associated with hearing loss could reveal new
82 molecular players involved in the condition and potential therapeutics.

83 Here, we describe a large Brazilian family in which hearing loss segregates as an
84 autosomal dominant trait. By linkage analysis and exome sequencing we identified a
85 rare missense variant in the gene *NCOA3* (NM_181659:c.2810C>G;p.Ser937Cys) that
86 segregated in the pedigree with hearing loss. We detected expression of the gene in
87 mice and zebrafish ears. Using CRISPR/Cas9 genome editing, we generated a zebrafish
88 *ncoa3*^{-/-} which showed cartilage behaviour abnormalities in the larval sensorial region
89 of the ear, amorphous material accumulation in proximity with adult otoliths, higher
90 mineral density and abnormal adult swimming behaviour. Our work provides evidence
91 of *NCOA3* playing an important role in skeletal system homeostasis and suggests
92 *NCOA3* as a potential candidate gene associated with hearing impairment.

93 **Results**

94 **Clinical findings in patients of a family with autosomal dominant, non-syndromic,**
95 **sensorineural hearing loss**

96 The five-generation Brazilian family examined in this study presented
97 individuals affected by nonsyndromic, progressive, sensorineural, bilateral, moderate-
98 to-profound hearing loss, segregating as an autosomal dominant condition (Figure 1A).
99 Affected and non-affected individuals were submitted to audiological tests (Figure 1B).
100 Age of onset of hearing loss varied from 4 to 35 years, with the average age of onset
101 being 12 years old (Table 1).

102 We performed ear, nose and throat (ENT) physical examinations. Patients III-5,
103 III-8, III-10, IV-20 and IV-21, showed normal results, as well as normal computed
104 tomography scan of temporal bones, magnetic resonance imaging of the inner ear and
105 thyroid ultrasound. IV-20 and IV-21 had bilateral mild earlobe hypogenesis. IV-21
106 showed coloboma auris. Other minor clinical findings were also observed. IV-5, IV-6:
107 bifid uvula at oropharynx cavity examination; III-8 and III-10: normal responses from
108 the otoneurological evaluation, including electrooculography with caloric tests; and III-
109 5: despite the absence of vestibular complaints, showed right idiopathic vestibular
110 weakness on caloric test.

111 **Linkage analysis points to a region of 13.5Mb on chromosome 20**

112 LOD score values from SNP-array analysis, assuming both complete ($K= 1$) and
113 incomplete ($K= 0.8$ and $K=0,64$) penetrance suggested linkage to chromosome
114 20(chr20:40201234-53724200, 64 and 88 cM, GRCh37/hg19), with maximum positive
115 value of 1.806 ($K= 1$; Figure 1D) and 1.805 ($K= 0.8$ and $K= 0,64$). This region has 13,5
116 Mb and contains 161 genes. We selected twelve microsatellite markers mapped along
117 chromosome 20 (Supplementary Figure 1), which confirmed our SNP-array analysis

118 pointing to a candidate region between 58 and 79 cM (complete penetrance, $K= 1$,
119 maximum Lod score= 1.006) and between 56 and 83 cM (incomplete penetrance, $K=$
120 0.8 and $K= 0,64$, maximum Lod score=2.286). No other chromosomal region showed
121 higher Lod scores than the ones obtained in chromosome 20. The maximum two-point
122 LOD score value for this genealogy was simulated for complete ($k=1$) and incomplete
123 ($K= 0.8$ and $K= 0,64$) penetrance resulting in 4.214, 3.580 and 3.145, respectively.

124 **Variant in *NCOA3* identified as candidate for hearing loss by whole-exome** 125 **sequencing**

126 We conducted whole-exome sequencing in samples from two of the affected
127 individuals (III-8 and III-10) (Figure 1A); obtaining approximately 70M reads per
128 sample (read average length of 99 bp, average coverage of 120X and 98% of target
129 bases with more than 20 reads). We selected autosomal, exonic, heterozygous and
130 nonsynonymous variants with $Q >30$ and coverage > 20 , checked them against public
131 variant databases and 66 control samples (sequenced simultaneously), and filtered for
132 variants with frequencies lower than 0.01. A total of 162 variants shared by both
133 samples were obtained (Table 2; Supplementary Table 1). From these variants, only the
134 NM_181659: c.2810C>G: p.S937C in *NCOA3* gene matched the suggestive positive
135 LOD score region mapped in the chromosome 20, as indicated by the linkage analysis.

136 Only two variants were detected in genes previously described as associated to
137 hearing loss: NM_001258370: c.A1565G:p.Gln522Arg (*DIAPH3*) and NM_005709:
138 c.G946C:p.Glu316Gln (*USH1C*). The variants in *DIAPH3* and *USH1C* were
139 investigated in the pedigree by Sanger sequencing, and their segregation was not
140 compatible with the segregation of hearing loss in the family (Supplementary Figure 2).
141 Moreover, copy-number variation was excluded after array-CGH (Agilent
142 Technologies, 180K).

143 *NCOA3* (Nuclear Receptor Coactivator 3) comprises 23 exons, encoding a
144 protein of 1420 amino acids, with a suggested function in the regulation of gene
145 transcription, mediated by nuclear receptors and it has never been reported to be
146 associated with hearing loss. The variant c.2810C>G in exon 15 is predicted to result in
147 a p.Ser937Cys amino acid substitution within a highly conserved region among
148 primates (Figures 1E and F). This variant was predicted to be damaging using several
149 prediction tools: SIFT showed a damaging score of 0.030, and Polyphen2, a score of
150 0.905. MutationTaster2 predicted that it is a disease-causing mutation (score of 0.845).
151 The variant, rs142951578, within *NCOA3* has been reported with low frequency by
152 GnomAD (0.0003465), NHLBI-ESP (0.000538), 1000 genomes (0.001) and was not
153 described by ABraOM.

154 We investigated the segregation of NM_181659: c.2810C>G: p.Ser937Cys in
155 *NCOA3* by Sanger sequencing in 19 samples. This variant was found to be present in
156 heterozygosis in all seven affected individuals and in 4 non-affected ones (Figure 1A
157 and 1C). These four heterozygous non-affected individuals are within the range of onset
158 of hearing loss observed in the family (4-35 years, Table 1), therefore, it is possible that
159 manifestation of hearing loss will occur later.

160 ***Ncoa3* is expressed in the developing mouse cochlea and zebrafish ear**

161 *Ncoa3* expression in mice has been reported for ovary, testis, liver, skeletal
162 muscle and adipose tissue (45–47), and transcriptome studies have suggested its
163 expression in the ear (48,49), however this has been poorly characterised. To determine
164 the temporal pattern of *Ncoa3* expression in the inner ear of mice we performed RT-
165 PCR and immunofluorescence on histological sections for 3 distinctive developmental
166 stages: P4, P10 and P16. *Ncoa3* expression was detected in the cochlea and the organ of
167 Corti with *stria vascularis* in all the time-points (Figure 2A and B). In addition to these

168 structures, immunofluorescence showed cytoplasmic localisation of *Ncoa3* in the
169 Reissner membrane, basilar membrane, spiral limbus and spiral ganglion (Figure 2B).
170 Zebrafish have only one ortholog of *NCOA3*. Whole mount *in situ* hybridization in
171 zebrafish showed *ncoa3* expression in the otic vesicle of 3 and 5dpf zebrafish larvae
172 (Figure 2C). Interestingly, there was continued expression even after the ear system is
173 completely developed, as detected in the inner ear of juvenile fish (5 and 7wpf, weeks
174 post fertilization) (Figure 2C). *ncoa3* expression was not detected in neuromasts
175 (mechanosensory system able to detect small water vibrations). Therefore, our results
176 suggest a conserved expression pattern of *Ncoa3* in the ear.

177 **Zebrafish *ncoa3*^{bi456/bi456} show cartilage cell behaviour abnormality in the otic**
178 **vesicle.**

179 In order to investigate the potential role of *NCOA3* in the pathogenesis of
180 hearing impairment, we generated *ncoa3* homozygous zebrafish mutants using
181 CRISPR/Cas9 genome editing. *ncoa3*^{bi456/bi456} (*ncoa3*^{-/-}) carry a 5bp deletion
182 (delTACGA) leading to a premature stop codon at position 518aa (S518_Y1520del),
183 reducing the protein size from 1520aa to 517aa. Human and zebrafish sequence
184 alignment showed conservation of 2 out of 5bp within the deletion site. A deleterious
185 effect was predicted when simulating the same mutation in the human ortholog.

186 *NCOA3* has been previously associated, through GWAS studies, with
187 osteoarthritis, bone mass, abnormal cartilage behaviour, and notch signalling pathway
188 (50–54). To investigate chondrocyte behaviour and sensory cells expressing notch in the
189 zebrafish ear, we crossed *ncoa3*^{bi456/bi456} to a double transgenic line carrying
190 Tg(*col2:mcherry*; *notch:egfp*). Zebrafish *ncoa3*^{bi456/bi456} did not display any major
191 morphological abnormalities of the ear at 5dpf (Supplementary Figure 3A and B).
192 Surprisingly, we detected abnormal clusters of cartilage cells (*mcherry* positive) lining

193 the cristae region in 95% of larvae (Figure 3A). 3D image analysis showed tight
194 association of abnormal cartilage cells with notch positive sensory cells (Figure 3A). To
195 examine if detachment of cartilage cells from main cartilage elements (exostosis) was
196 disrupting the hair cells, we measured the lengths of the stereocilia and cupula of the
197 lateral and anterior cristae at 5dpf and no significant differences were detected
198 (Supplementary Figure 3C).

199 In addition, phalloidin staining, which labels actin filaments of the stereocilia,
200 was performed to evaluate stereocilia of other regions of the ear. Interestingly, we
201 detected disorganised distribution of stereocilia of the macula (4/4 of *ncoa3*^{-/-} and 0/3
202 wt) (Figure 3B). We investigated earlier stages of development (2-3dpf) to understand
203 when chondrocytes were first misplaced. While at 2dpf no differences were detected, by
204 3dpf ectopic chondrocytes were observed at the cristae and internal regions of the ear
205 canal (Supplementary Figure 4). This suggests exostosis of cartilage cells from the ear
206 cartilage layer towards the cristae regions and internally. We did not detect changes in
207 the neuromasts throughout the larvae, neither in the lateral line (data not shown). We
208 also did not observe differences in larval swimming behaviour of *ncoa3*^{bi456/bi456} at 5dpf
209 (data not shown). Our results suggest abnormal cartilage behaviour (exostosis) and
210 disruption of stereocilia organisation in the macula as a potential progressive and subtle
211 mechanism underlying hearing loss.

212 **Higher bone density and ectopic mineralisation within the ear of adult *ncoa3*** 213 *bi456/bi456*

214 Otoliths consist of a proteinaceous core that is biomineralized by calcium
215 carbonate; in the adult fish ear, a single otolith is tethered to each of the utricular,
216 saccular and lagenal sensory maculae allowing sensation of linear accelerations and
217 sound (55). It has been shown that mutations in *Otogelin* and α -*Tectorin* impair otolith

218 seeding (56), and mutations in their human orthologs *OTOG* and *TECTA* cause
219 deafness. Therefore, the shape and density of otoliths are indicative of possible defects
220 in the hearing system. *ncoa3*^{bi456/bi456} survive to adulthood and are fertile. To analyse the
221 3D structure of the adult ears, we performed micro-computerised tomography (μ CT) of
222 1 year old mutants (n= 8) and wts (n= 25). We observed higher bone mineral density of
223 craniofacial bones of *ncoa3*^{bi456/bi456} and abnormal and disorganised mineralisation of
224 amorphous material was detected in 75% (6/8) of the ears of *ncoa3*^{bi456/bi456}, but was
225 never observed in wt (Figure 4A). This mineralisation was attached to the lagenal
226 otoliths, which is clearly observed through cross sections (Figure 4A, arrows). We did
227 not detect abnormalities in the utricular and saccular otoliths. Moreover, otoliths
228 showed increased bone mineral density in mutants (Figure 4A and C). Therefore, these
229 results suggest a role of *ncoa3* in bone and ectopic mineralisation regulation in the ears
230 that could lead to progressive hearing impairment in adult fish. It has been shown that
231 vestibular function can be assessed through swimming behaviour analyses (57).
232 Therefore, to test if the fish displayed any signs of hearing loss we analysed swimming
233 behaviour by tracking individual fish in 2D in a tank containing a shaded corner, and
234 calculating the spatial distribution heterogeneity of fish under constant ambient
235 background noise. Vestibular malfunction has been associated to abnormal exploratory
236 behaviour in zebrafish (57). We hypothesised that if hearing function is altered in
237 *ncoa3*^{bi456/bi456}, these fish would display a distinct exploratory behaviour, dispersing
238 from the shaded corner of the tank more often than the wt. While the wt was retained
239 mostly to the shady corner, interestingly the *ncoa3*^{bi456/bi456} showed increased spatial
240 distribution heterogeneity, detected through the comparison of total trajectory
241 distribution between both groups (Figure 5). Our results suggest possible hearing

242 malfunctioning in *ncoa3*^{bi456/bi456} due to differences in bone densities, and ectopic

243 mineral deposition.

244

245 **Discussion**

246 Non-syndromic hearing loss is a condition that affects almost 466 million people
247 worldwide and is characterized by a broad heterogeneity of causes, among them genetic
248 factors play an outstanding role (2). Reported genes and variants associated with
249 monogenic forms of the disease have been identified from independent pedigrees and
250 the rarity of some variants implies that some candidates are hardly reproducible.
251 Therefore, functional studies are key to support genetic findings. In this sense, animal
252 models such as mice and zebrafish are valuable and have proved relevant to the
253 investigation of molecular mechanisms that underlie hearing loss in humans (56,58–60).
254 The molecular and cellular mechanisms involved in ear development and homeostasis
255 are highly conserved through evolution and zebrafish have been used elsewhere to study
256 ear development and to confirm candidate genes involved in hearing loss (61–65).

257 Here, combining linkage analysis with exome sequencing and functional
258 analysis we have reported for the first time an association between segregation of a rare
259 variant in *NCOA3* and hearing loss, suggesting a novel mechanism leading to the
260 pathogenesis of hearing impairment. *NCOA3* is a nuclear receptor coactivator from the
261 *NCOA* gene family, positively regulating nuclear receptor-mediated gene transcription
262 (66). We identified a missense variant in *NCOA3*, c.2810C>G: p.Ser937Cys, of which
263 computation predictions and frequency are compatible with the hypothesis of this
264 variant being causative of hearing loss. We have provided further expression data in
265 mice and zebrafish ears, that point to evolutionary conservation of gene function in the
266 ear. Moreover, through CRISPR/Cas9 we have generated a *ncoa3* zebrafish knockout to
267 further investigate the effects of loss of function of *ncoa3* in the ear during development
268 and ageing.

269 NCOA3 function has been linked to reproductive development and physiology
270 regulation (67–70), pluripotency regulation (71), neurotransmitter metabolism
271 regulation (72), adipogenesis promotion (73), long-chain fatty acid metabolism
272 regulation (47). In mice, although around 10% of the knockout animals for *Ncoa3*
273 exhibit a unilateral drop of the ear (74), they were not submitted to audiological
274 evaluation. In a previous transcriptome analysis study of mice tissue, *Ncoa3* expression
275 has been reported in organ of Corti of E16, P0, P4 and P7 C57BL/6, with more
276 pronounced expression levels observed in the postnatal phases (48). Transcriptome
277 analysis of inner and outer hair cells from P25-P30 CBA/J mice cochleae also indicated
278 expression of *Ncoa3* (49). Our results not only confirmed *Ncoa3* expression in the organ
279 of Corti of P4 mice, but also complemented the aforementioned studies, showing that
280 the gene is still active in more advanced ages, near the end of cochlea maturation (P10
281 and P16). Moreover, we showed evidence of NCOA3 protein expression in the mice
282 hearing system. Protein expression has been detected in all mice ages studied (P4, P10
283 and P14), with expression pattern spread along several cochlear structures: basilar
284 membrane, Reissner membrane, organ of Corti, *stria vascularis*, spiral limbus and spiral
285 ganglion. Altogether, our results suggest that *Ncoa3* may have an important role in the
286 development and physiology of mice auditory system.

287 We also detected expression of *ncoa3* in zebrafish during and after the
288 completion of the inner ear development. In addition to the inner ear, fish have another
289 component to their mechanosensory system; the lateral line, which is also formed by
290 hair cells, supporting cells and sensory neurons, forming units called neuromasts which
291 are key during the startle swim behaviour response (75,76). Although there are genes
292 that are expressed both in the inner ear and lateral line, such as *atoh1a* (77,78) and *ngn1*
293 (79) and that larval behaviour is observed when such genes are knocked out, *ncoa3* does

294 not follow this pattern, as we did not detect its expression in the neuromasts or changes
295 to larval startle swim behaviour response in zebrafish *ncoa3*^{bi456/bi456}.

296 Functional analysis carried in zebrafish *ncoa3*^{bi456/bi456} showed that *ncoa3* is
297 dispensable for development of the inner ear, but it is important for the maintenance the
298 skeletal system. Although we did not detect morphological changes (size and shape of
299 ear) in larval stages, abnormal cartilage cell behaviour was a predominant phenotype in
300 larval *ncoa3*^{bi456/bi456}. In adults, denser craniofacial bones and otoliths, and ectopic
301 mineralisation in the ears were detected. Abnormal invading cartilage cells could
302 potentially contribute to ectopic mineralisation in the vestibular region during ageing.
303 Recent studies inferred *NCOA3* involvement in maintaining skeletal homeostasis, with
304 evidence of its function in bone mass (53), behaviour and molecular signature of
305 chondrocytes (80,81). Thus, sustaining its role in regulation of bone density and
306 cartilage behaviour, respectively. Changes in bone mineral density have also been
307 associated with hearing loss. Loss of bone mineral density in the cochlea capsule has
308 been related to hearing loss in Paget's disease (osteoclast/bone resorption disorder (82)).
309 Mutations in *SOST* (sclerostosis and van Buchem's disease) cause enhanced bone
310 formation, higher bone mineral density, and calvaria overgrowth, which frequently
311 compresses cranial nerves leading to hearing loss (83). Although computed tomography
312 scans of temporal bones revealed normal bone morphology in affected individuals from
313 the pedigree, it would be interesting to further investigate overall calvarial bone
314 thickness and bone mineral density in the family, as such data are currently unavailable.
315 Moreover, computed tomography is not sensitive enough to detect possible subtle
316 changes at the cellular level that could be contributing to hearing loss as suggested by
317 our functional analysis.

318 Altered swimming behaviour was previously detected when mutant larvae for
319 several hearing loss associated genes were analysed, such as *grhl2b*, *myo7aa*, *cdh23*,
320 *otofa* and *otofb* (84,85). Mutations in the human orthologs are associated with mild to
321 severe hearing loss (86–89). The respective zebrafish mutants have severe abnormalities
322 in the inner ear, otoliths and/or lateral line, and recapitulate abnormalities of those
323 observed in human patients. However, they differ from subtle and progressive changes
324 involved in *ncoa3* zebrafish mutants and the family that we described. We did not
325 observe larval behaviour changes in *ncoa3*^{-/-} (data not shown). But we observed adult
326 behaviour changes that fit with progressive hearing loss. While assessment of hearing
327 loss through adult swimming behaviour in zebrafish is not well explored yet, it has been
328 shown that when adult zebrafish are introduced into a centre of a magnetic field they
329 exhibited altered exploratory behaviour due to vestibular malfunction and independent
330 of lateral line function (57). Therefore, vestibular function can be assessed by
331 exploratory behaviour changes. In a new environment under constant background noise,
332 we would expect that fish carrying hearing disability would display altered behaviour.
333 Ectopic mineral deposition within the ears of adult mutant zebrafish and increased
334 density of otoliths and craniofacial bones are potentially correlated with the altered
335 vestibular function and swimming behaviour found in adult mutants.

336 Although family size does not allow a definite conclusion about the c.2810C>G
337 variant being causative to hearing loss, our functional results were compatible with the
338 hypothesis of *NCOA3* playing a role in hearing, suggesting skeletal homeostasis
339 (cartilage behaviour and bone density) as a strong factor involved in the condition. Our
340 contribution was to attract further attention to *NCOA3* as possibly involved in hearing,
341 since many groups are dealing with patient samples revealing hundreds of candidate
342 variants after exome sequencing, without clues to find the causative one. Further

343 functional studies to evaluate the precise effect of the missense variant p.Ser937Cys in
344 *NCOA3* function would add value in understanding age-related hearing loss in patients
345 with autosomal dominant pathogenic variants in *NCOA3*.

346

347 **Materials and Methods**

348 **Patients**

349 A large Brazilian family comprising 5 generations and 15 reported affected
350 individuals with hearing loss was ascertained in our genetic counselling unit (Centro de
351 Pesquisas sobre o Genoma Humano e Células-Tronco - IBUSP) for molecular studies.
352 The transmission of hearing loss in the pedigree is compatible with autosomal dominant
353 inheritance (Figure 1A). For molecular studies, DNA samples from 19 individuals were
354 collected: 7 from affected individuals (III-5, III-8, III-10, IV-6, IV-9, IV-21, IV-22), and
355 12 from unaffected individuals, including spouses (II-4, III-11, IV-5, IV-12, IV-15, IV-
356 17, IV-18, IV-19, IV-20, V-3, V-5 e V-6). Written informed consent was obtained from
357 every participant or the respective guardians. The study was approved by the Ethics
358 Committee from Instituto de Biociências da Universidade de São Paulo.

359 **Audiological evaluation**

360 Pure tone audiometry, both air (frequencies ranging from 250 to 8000Hz) and
361 bone conduction (frequencies ranging from 500 to 4000Hz) were performed for
362 identification of hearing threshold levels in seven affected individuals (III-5, III-8, III-
363 10, IV-6, IV-9, IV-21 and IV-22) and eleven non-affected individuals (III-11, IV-5, IV-
364 12, IV-15, IV-17, IV-18, IV-19, IV-20, V-3, V-5 and V-6). Most of these exams were
365 done at DERDIC (Divisão de Educação e Reabilitação dos Distúrbios da Comunicação,
366 PUCSP), while some were conducted by other institutions prior to this study.

367 **SNP-array and microsatellite markers genotyping**

368 Genomic DNAs from seven affected individuals (III-5; III-8 III-10; IV-6; IV-9;
369 IV-21; IV-22) were submitted to SNP-Array (50K) assays (Affymetrix GeneChip
370 HumanMapping 50K Array, Affymetrix), using the manufacturer's reagents (XbaI) and
371 following the GeneChip Mapping 10K 2.0 Assay Manual. Scanning was performed in a

372 Genechip Scanner 3000 and interpreted with Affymetrix Genotyping Console software
373 (Affymetrix). In addition, twelve polymorphic microsatellite markers mapped to
374 chromosome 20 (ABI Prism Linkage Mapping Sets v2.5) were genotyped in 16 samples
375 (II-4, III-5, III-8, III-10, IV-5, IV-6, IV-9, IV-12, IV-16, IV-17, IV-18, IV-19, IV-20,
376 IV-21, IV-22, V-3).

377 **Lod score calculations**

378 Penetrance of hearing loss was estimated according to methods previously
379 described (19). The most likely value of penetrance was $K= 0.6364$. Multipoint
380 logarithm of odds (LOD) score values were calculated, for each autosome, using Merlin
381 program (20) under dominant inheritance model, assuming a rare allele (frequency=
382 0.001). The LOD score calculations were performed considering penetrance of $K=$
383 0.6364, but also under the assumption of penetrance $K= 0.8$ and complete penetrance,
384 $K= 1$.

385 **Whole-exome sequencing**

386 DNA samples from two affected individuals (III-8 and III-10) were submitted to
387 whole-exome sequencing. The library was prepared with Nextera rapid capture kit
388 (Illumina), sequence capture was performed with Illumina Exome enrichment kit (~62
389 Mb target size) and sequencing was performed using HiSeq 2500. Fastq files were
390 aligned against reference GRCh37 with Burrows-Wheeler Aligner (BWA) (21),
391 realignment of indel regions, discovery of variants and recalibration of base qualities
392 were performed using GATK software (22) for the production of VCF files; the VCF
393 was annotated by ANNOVAR software (23). Variant frequencies were compared with
394 public variant databases: 1000 Genomes (24), National Heart, Lung, and Blood Institute
395 Exome Sequencing Project (NHLBI-ESP) (25), Genome Aggregation Database
396 (gnomAD) (26) and Online Archive of Brazilian Mutations (ABraOM) (27). Polyphen-

397 2 (28), SIFT (29), Provean (30) and MutationTaster2 (31) were used for *in silico*
398 damage prediction to the protein. Protein sequence alignment near the best candidate
399 variant was performed by Clustal Omega alignment program (32).

400 **Sanger sequencing**

401 The DNA regions containing candidate variants filtered after exome sequencing
402 were amplified by PCR. The products were bi-directionally Sanger sequenced with the
403 BigDye Terminator v3.1 Cycle Sequencing Kit (ThermoFisher Scientific) in ABI 3730
404 DNA Analyzer (Applied Biosystems). *NCOA3F*-
405 5'GGCTGTACTTACATGGTATAAGAAGG3', *NCOA3R*-
406 5'AGGGGAGGGTGGACACTTAC3', *DIAPH3F* -
407 5'CAAGGGTTTCTGTGCATACC3', *DIAPH3R* -
408 5'CACTACTCGTTAGTAAATGGAAGGG3', *USH1CF* -
409 5'GCTGAGAAGACCACCTGCAT3', *USH1CR*-
410 5'GAGGAGGAGGAAGTTGGCTG3' were used as primers. Sequences were analysed
411 using Bioedit (Ibis Biosciences).

412 **Multiple alignment of *NCOA3* and its orthologous**

413 Multiple alignment of *NCOA3* gene and protein with its orthologous was
414 performed using Clustal Omega provided by European Bioinformatics Institute (EMBL-
415 EBI) (33). For this purpose, the following sequences were used: *Homo sapiens*
416 (NM_181659.2 and NP_858045.1); *Pan troglodytes* (XM_016938072.2 and
417 XP_016793561.2); *Macaca mulatta* (XM_015148801.1 and XP_015004287.1); *Bos*
418 *Taurus* (XM_002692493.4 and XP_002692539.1); *Mus musculus* (NM_008679.3 and
419 NP_032705.2); *Rattus norvegicus* (XM_006235634.2 and XP_006235696.2); *Gallus*
420 *gallus* (XM_004947056.2 and XP_004947113.2); *Danio rerio* (XM_687846.9 and
421 XP_692938.5) *Xenopus tropicalis* (XM_018097860.1 and XP_017953349.1).

422 **Mice husbandry**

423 CBL57/6 mice were obtained from Centro de Pesquisas sobre o Genoma
424 Humano e Células-Tronco (IBUSP) experimentation housing facility. The animals were
425 housed as previously described by Council for International Organizations of Medical
426 Sciences (CIOMS) (34). All experiments with mice were ethically approved by the
427 Internal Review Board on Ethics in Animal Research from the Instituto de Biociências
428 da Universidade de São Paulo (Process Number 16.1.668.41.6).

429 **Cochleae and organ of Corti dissection**

430 Cochleae and organ of Corti with *stria vascularis* were harvested from CBL57/6
431 decapitated mice at 4, 10, 14 and 16 day-old (P4-P16) postnatal CBL57/6 mice. After
432 decapitation, the head was bathed in ethanol 70%, followed by longitudinal incision at
433 the skull's sagittal line and visualization of the temporal bone, allowing the dissection
434 of the labyrinth. For RNA extraction, the labyrinths were transferred to a Petri dish with
435 RNAlater® (Sigma Aldrich). Cochlea and organ of Corti with *stria vascularis* were
436 then surgically harvested with micro tweezers (Dumont #5 e #54, Koch Electron
437 Microscopy) under trinocular stereomicroscope (Discovery V12, Carl Zeiss). For
438 immunofluorescence assays, cochleae were isolated from labyrinths kept in phosphate
439 buffered saline (PBS), using micro tweezers (Dumont #5 e #54, Koch Electron
440 Microscopy) under trinocular stereomicroscope (Discovery V12).

441 **RT-PCR**

442 Total RNA extraction was performed with a pool of 12 cochleae or 12 organs of
443 Corti with *stria vascularis* from P4, P10 and P16 mice, as well as with gastrocnemius
444 sample of P180 mice. Total RNA was extracted with RNeasy Microarray Tissue Mini
445 Kit (QIAGEN). Synthesis of cDNA was performed with RNeasy Microarray Tissue
446 Mini Kit (QIAGEN), using 1µg of total RNA. Primers used for this experiment were:

447 *Ncoa3*F-5'CGTTTCTCCTTGGCTGATGG3', *Ncoa3*R-
448 5'CGGGATTTGGGTTTGGTCTG3', *Actb*F-5'GGCTGTATTCCCCTCCATCG3',
449 *Actb*R-5'CCAGTTGGTAACAATGCCATGT3', *B2m*F-
450 5'TCGCGGTCGCTTCAGTCGTC3', *B2m*R- 5'TTCTCCGGTGGGTGGCGTGA3'.

451 Control experiments concomitantly performed were negative control of cDNA synthesis
452 (using water instead of extracted RNA), negative control of RT-PCR (using water
453 instead of cDNA), and positive control (using cDNA synthesized from gastrocnemius
454 RNA). Housekeeping genes used as reference for this experiment were *Actb* and *B2m*.

455 **Immunofluorescence assays**

456 Cochleae preparation and immunofluorescence assays were performed as
457 described by (35). Cochleae were perfused locally and fixed in 4% paraformaldehyde
458 (PFA) at 4°C overnight (o/n). P10 and P14 passed through decalcification with 10%
459 EDTA and 1% PFA at 4°C for 4 days. All tissues were washed with 1X PBS, submitted
460 to serial dilutions of sucrose solution and Jung Tissue Freezing Medium (Leica
461 Microsystems), frozen and transversely cryosectioned in 12µm. Slides were stored at -
462 80°C until use. For immunofluorescence assays, histological slides were simultaneously
463 permeabilized and blocked with 0.3% triton X-100 and 4% bovine serum albumin
464 (BSA) solution, followed by incubation in solution containing 1:50 polyclonal anti-
465 NCOA3 antibody (anti-SCR3 antibody - ChIP Grade, Rabbit Polyclonal, ab2831,
466 Abcam Inc.) diluted in 0.1% triton X-100 and 4% BSA, at 4°C o/n. Subsequently, the
467 slides were incubated in solution containing 1:500 anti-rabbit AlexaFluor-568 diluted in
468 0.1% triton X-100, 1% BSA, at for 2h at room temperature. After rinse in PBS, the
469 slides were then mounted with Prolong Gold Antifade Reagent (Invitrogen) with DAPI
470 for nuclei staining. Images were taken confocal microscope either LSM 780 (Carl Zeiss)
471 or LSM880 (Carl Zeiss), using Zen software (Carl Zeiss).

472 **Zebrafish husbandry and lines**

473 Zebrafish were housed as previously described (36). Animal experiments were
474 ethically approved by the Animal Welfare and Ethical Review Body (AWERB) at the
475 University of Bristol and performed under a UK Home Office project and by the
476 Internal Review Board on Ethics in Animal Research from the Instituto de Biociências
477 da Universidade de São Paulo (Process Number 16.1.668.41.6). Transgenic lines used
478 have been previously described: *TgBAC(Col2a1a:mCherry)^{hu5910}* (37) and
479 *Tg(notch:egfp)* (38).

480 **Whole-mount *in situ* hybridization in zebrafish**

481 Whole-mount *in situ* hybridizations on zebrafish samples were performed as
482 described by (39). *ncoa3 in situ* probe was synthesised *in vitro* from a PCR product(880
483 bp amplified from exon11) using a T7 RNA Polymerase for transcription
484 (ThermoFisher Scientific) and DIG-labelling Mix (Roche) followed by purification with
485 SigmaSpin™ Post-Reaction Clean-Up Columns (Sigma Aldrich). The following
486 primers were used for the PCR: *ncoa3-F*
487 (5'GAATACCTTCTCTAGCAGCTCATTG3') and *ncoa3-R*
488 (5'taatacgaactcactatagggagCTTATTGAGGAGGTAGTGAAGGAGG3').

489 **Generation of zebrafish *ncoa3*^{-/-}**

490 *ncoa3* mutants were generated by CRISPR/Cas9 system as previously described
491 (40). A gRNA was designed to target *ncoa3*:
492 TGGGGTCTCCGCGGATACGAGGG(PAM) (chr11:18516059-18516081). Once
493 synthesised, it was incubated with GeneArt Platinum Cas9 nuclease (Invitrogen) prior
494 to injections into 1 cell stage zebrafish embryos. DNA was extracted from 20 individual
495 larvae at 2 days post fertilization (dpf), followed by PCR amplification (*ncoa3*CRISPR
496 F: FAM-ATGAATGAGCAAGGCCACAT; *ncoa3*CRISPR R:

497 GGACTTGCTCCCATTTTAGG) and subjected to fragment length analysis (ABI
498 3500) to test gRNA efficiency (90% efficiency rate detected). G0s were outcrossed to
499 generate G1s which were submitted to Sanger sequencing. The mutant line *ncoa3*^{bi456}
500 carries a 5bp deletion, leading to a premature stop codon predicted to undergo mRNA
501 nonsense mediated decay.

502 **Microscopy**

503 Samples were mounted in 1% low melting point (LMP) agarose (Invitrogen)
504 and imaged with a Leica SP5II confocal microscopy (Leica LAS software) using 10x
505 PL APO CS (dry), 20x immersion lens (phalloidin) or 40x PL APO CS (oil) lenses
506 (cristae imaging). LasX (Leica) and Amira 6.0 (FEI) was used for 2D and 3D
507 rendering, image analysis and picture acquisition.

508 **3D perspective measurements of the otic vesicle**

509 Two distinct 3D perspective measurements (sagittal/x axis and coronal/y axis)
510 were taken of the major axis of the otic vesicle at 5dpf from confocal images using
511 Amira 6.0. GraphPad (Prism) was used for statistical analysis. t-Tests (non-
512 parametric, Mann-Whitney U test, $p < 0.05$) were performed ($n = 7$ for each group).

513 **Phalloidin staining**

514 Larvae (5dpf) were fixed in 4% PFA at 4°C o/n, washed in PBS 3 x 5 minutes
515 and incubated in AlexaFluor 555 conjugated phalloidin (1:20 in PBS) o/n at 4°C
516 (protocol adapted from (41)). Samples were then washed in PBS 3 x 15 minutes,
517 mounted laterally in 0.5% LMP agarose and imaged on a confocal microscopy.

518 **Micro-computerised tomography (μ CT) and bone mineral density calculation**

519 Adult fish (1 year old) were fixed in 4% PFA for 1 week followed by sequential
520 dehydration to 70% ethanol. Fish heads were scanned using an XT H 225ST μ CT
521 scanner (Nikon) with voxel size of 20 μ m and 5 μ m for detailed geometric analysis,

522 using an x-ray source of 130 kV, 53 μ A and without additional filters. Images were
523 reconstructed using CT Pro 3D software (Nikon). Amira 6.0 was used for image
524 analysis and to generate 3D volume and surface renders. Lagena otoliths were
525 segmented from μ CT images (20 μ m resolution) and bone density was quantified by
526 sampling a region 20 slices thick at the centre of the otoliths. Greyscale values were
527 calibrated against phantom blocks with calibrated densities.

528 **Adult swimming behaviour analysis**

529 Swimming behaviour was assessed by recording 2D movement (from above) in
530 a rectangular tank. Individual fish (1 year old, wild type (wt) $n=7$ and *ncoa3*^{-/-} $n=6$)
531 were transferred to a tank (35cm \times 40cm) containing a shaded corner (10cm \times 10cm)
532 and a total of 8 L of water. The tank was placed in an environment of constant
533 background noise (\sim 80dB) and recorded with a digital camera (Basler acA2040-120 μ m)
534 at a frame rate of 15 frames/s, for 10 minutes (9000 frames). The 2D positions in
535 different frames were calculated by a custom Python script (42). Trajectories were
536 obtained by applying a four-frame best estimate algorithm (43) to the positions, and
537 further refined following the approach described in (44). For each fish, we calculated its
538 normalised 2D spatial distribution $P(N)$ where N is the number of times the fish stays in
539 a grid, whose size is 100 pixels by 100 pixels. We then calculated the standard deviation
540 of N in all grids as a proxy to the spatial distribution heterogeneity, noted as $Std(N)$.
541 The difference in the behaviours between the wt fish and the mutant fish is then
542 characterised by $Std(N)$ values of each individual. Assuming the spatial heterogeneity
543 of the wt fish and the mutant fish follow the normal distributions with different
544 variances, we used student t test to calculate the probability of their average values
545 being the same ($p < 0.05$ statistically significant).

546

547 **Acknowledgements**

548 EK and CH were funded by Versus Arthritis (19476, 21211). AK was funded by
549 BBSRC SWBio-DTP studentship and EL by a Wellcome Trust Dynamic Molecular
550 Cell Biology PhD studentship. This work was supported by Fundação de Amparo à
551 Pesquisa do Estado de São Paulo (FAPESP - CEPID Human Genome and Stem-Cell
552 Research Center 2013/08028-1), Coordenação de Aperfeiçoamento de Pessoal de Nível
553 Superior – CAPES and Conselho Nacional de Desenvolvimento Científico e
554 Tecnológico (CNPq, grant 133182/2015-0). The authors are indebted to all
555 professionals of Divisão de Educação e Reabilitação dos Distúrbios da Comunicação
556 (DERDIC) da Pontifícia Universidade Católica de São Paulo, São Paulo (PUC-SP), in
557 special to Márcia Zucheratto, for audiological evaluations. We thank Dr. Maria Rita
558 Passos-Bueno for support on establishing the zebrafish laboratory at Instituto de
559 Biociências da Universidade da São Paulo (IBUSP) and Dr. Marília O. Scliar for
560 bioinformatics assistance. We also thank Ms. André S. Bueno for assistance and Drs.
561 Erika Freitas and Carla Rosenberg for Array-CGH.

562

563 **Author contributions**

564 RSS, VLGD, FSN, BCN, EL, AK, YY and EK performed experiments. RSS, VLGD,
565 LUA, ACB, JO, EL, AK, YY, RCMN and EK analysed data. The project was designed
566 by RCMN (gene identification) and EK (functional analysis). All authors contributed to
567 drafting the manuscript.

568

569 **Conflicts of interest**

570 We declare no competing interests.

571

572

573

574 **References**

575

- 576 1. WHO | World Health Organization. WHO | World Health Organization
577 <http://www.who.int> (accessed Aug 23, 2018).
- 578 2. Shearer, A. E., Hildebrand, M. S. and Smith, R. J. (1993) Hereditary Hearing Loss
579 and Deafness Overview. In Adam, M. P., Ardinger, H. H., Pagon, R. A., et al.
580 (eds.), *GeneReviews*®, University of Washington, Seattle, Seattle (WA).
- 581 3. Keats, B. J. B. and Berlin, C. I. (1999) Genomics and Hearing Impairment. *Genome*
582 *Res.*, **9**, 7–16.
- 583 4. Vona, B., Nanda, I., Hofrichter, M. A. H., et al. (2015) Non-syndromic hearing loss
584 gene identification: A brief history and glimpse into the future. *Mol. Cell. Probes*,
585 **29**, 260–270.
- 586 5. Brownstein, Z., Friedman, L. M., Shahin, H., et al. (2011) Targeted genomic
587 capture and massively parallel sequencing to identify genes for hereditary hearing
588 loss in middle eastern families. *Genome Biol.*, **12**, R89.
- 589 6. Diaz-Horta, O., Duman, D., Li, J. F., et al. (2012) Whole-Exome Sequencing
590 Efficiently Detects Rare Mutations in Autosomal Recessive Nonsyndromic Hearing
591 Loss. *PLOS ONE*, **7**, e50628.
- 592 7. Wu, C.-C., Lin, Y.-H., Lu, Y.-C., et al. (2013) Application of Massively Parallel
593 Sequencing to Genetic Diagnosis in Multiplex Families with Idiopathic
594 Sensorineural Hearing Impairment. *PLOS ONE*, **8**, e57369.
- 595 8. Pandya, A. (2016) Genetic hearing loss: the journey of discovery to destination –
596 how close are we to therapy? *Mol. Genet. Genomic Med.*, **4**, 583–587.
- 597 9. Welcome to the Hereditary Hearing Loss Homepage | Hereditary Hearing Loss
598 Homepage. Welcome to the Hereditary Hearing Loss Homepage | Hereditary
599 Hearing Loss Homepage <https://hereditaryhearingloss.org/> (accessed May 3, 2020).
- 600 10. Zhao, H.-B., Kikuchi, T., Ngezahayo, A., et al. (2006) Gap Junctions and Cochlear
601 Homeostasis. *J. Membr. Biol.*, **209**, 177.
- 602 11. Lynch, E. D., Lee, M. K., Morrow, J. E., et al. (1997) Nonsyndromic Deafness
603 DFNA1 Associated with Mutation of a Human Homolog of the Drosophila Gene
604 diaphanous. *Science*, **278**, 1315–1318.
- 605 12. Belyantseva, I. A., Boger, E. T., Naz, S., et al. (2005) Myosin-XVa is required for
606 tip localization of whirlin and differential elongation of hair-cell stereocilia. *Nat.*
607 *Cell Biol.*, **7**, 148–156.
- 608 13. Vahava, O., Morell, R., Lynch, E. D., et al. (1998) Mutation in Transcription Factor
609 POU4F3 Associated with Inherited Progressive Hearing Loss in Humans. *Science*,
610 **279**, 1950–1954.
- 611 14. Collin, R. W. J., Kalay, E., Tariq, M., et al. (2008) Mutations of ESRRB Encoding
612 Estrogen-Related Receptor Beta Cause Autosomal-Recessive Nonsyndromic
613 Hearing Impairment DFNB35. *Am. J. Hum. Genet.*, **82**, 125–138.
- 614 15. Hilgert, N., Smith, R. J. H. and Van Camp, G. (2009) Forty-six genes causing
615 nonsyndromic hearing impairment: Which ones should be analyzed in DNA
616 diagnostics? *Mutat. Res. Mutat. Res.*, **681**, 189–196.
- 617 16. Gariballa, N., Ben-Mahmoud, A., Komara, M., et al. (2017) A novel aberrant splice
618 site mutation in COL27A1 is responsible for Steel syndrome and extension of the
619 phenotype to include hearing loss. *Am. J. Med. Genet. A.*, **173**, 1257–1263.

- 620 17. Booth, K. T., Askew, J. W., Talebizadeh, Z., et al. (2019) Splice-altering variant in
621 COL11A1 as a cause of nonsyndromic hearing loss DFNA37. *Genet. Med. Off. J.*
622 *Am. Coll. Med. Genet.*, **21**, 948–954.
- 623 18. Nixon, T. R. W., Alexander, P., Richards, A., et al. (2019) Homozygous Type IX
624 collagen variants (COL9A1, COL9A2, and COL9A3) causing recessive Stickler
625 syndrome-Expanding the phenotype. *Am. J. Med. Genet. A.*, **179**, 1498–1506.
- 626 19. Rogatko, A., Pereira, C. A. and Frota-Pessoa, O. (1986) A Bayesian method for the
627 estimation of penetrance: application to mandibulofacial and frontonasal dysostoses.
628 *Am. J. Med. Genet.*, **24**, 231–246.
- 629 20. Abecasis, G. R., Cherny, S. S., Cookson, W. O., et al. (2002) Merlin—rapid
630 analysis of dense genetic maps using sparse gene flow trees. *Nat. Genet.*, **30**, 97–
631 101.
- 632 21. Li, H. and Durbin, R. (2009) Fast and accurate short read alignment with Burrows–
633 Wheeler transform. *Bioinformatics*, **25**, 1754–1760.
- 634 22. McKenna, A., Hanna, M., Banks, E., et al. (2010) The Genome Analysis Toolkit: A
635 MapReduce framework for analyzing next-generation DNA sequencing data.
636 *Genome Res.*, **20**, 1297–1303.
- 637 23. Wang, K., Li, M. and Hakonarson, H. (2010) ANNOVAR: functional annotation of
638 genetic variants from high-throughput sequencing data. *Nucleic Acids Res.*, **38**,
639 e164–e164.
- 640 24. 1000 Genomes | A Deep Catalog of Human Genetic Variation. 1000 Genomes | A
641 Deep Catalog of Human Genetic Variation <https://www.internationalgenome.org/>
642 (accessed Aug 16, 2019).
- 643 25. Exome Variant Server. Exome Variant Server <https://evs.gs.washington.edu/EVS/>
644 (accessed Aug 16, 2019).
- 645 26. gnomAD. gnomAD <https://gnomad.broadinstitute.org/> (accessed Aug 16, 2018).
- 646 27. ABraOM: Brazilian genomic variants. ABraOM: Brazilian genomic variants
647 <http://abraom.ib.usp.br/> (accessed Aug 16, 2018).
- 648 28. Adzhubei, I. A., Schmidt, S., Peshkin, L., et al. (2010) A method and server for
649 predicting damaging missense mutations. *Nat. Methods*, **7**, 248–249.
- 650 29. Ng, P. C. and Henikoff, S. (2006) Predicting the Effects of Amino Acid
651 Substitutions on Protein Function. *Annu. Rev. Genomics Hum. Genet.*, **7**, 61–80.
- 652 30. Choi, Y., Sims, G. E., Murphy, S., et al. (2012) Predicting the Functional Effect of
653 Amino Acid Substitutions and Indels. *PLOS ONE*, **7**, e46688.
- 654 31. Schwarz, J. M., Cooper, D. N., Schuelke, M., et al. (2014) MutationTaster2:
655 mutation prediction for the deep-sequencing age. *Nat. Methods*, **11**, 361–362.
- 656 32. Clustal Omega < Multiple Sequence Alignment < EMBL-EBI. Clustal Omega <
657 Multiple Sequence Alignment < EMBL-EBI
658 <https://www.ebi.ac.uk/Tools/msa/clustalo/> (accessed Aug 16, 2019).
- 659 33. Madeira, F., Park, Y. M., Lee, J., et al. (2019) The EMBL-EBI search and sequence
660 analysis tools APIs in 2019. *Nucleic Acids Res.*, **47**, W636–W641.
- 661 34. Research, N. R. C. (US) I. for L. A. (2004) International Guiding Principles for
662 Biomedical Research Involving Animals (1985). *International Guiding Principles*
663 *for Biomedical Research Involving Animals (1985)*; National Academies Press
664 (US), (2004) .
- 665 35. Smeti, I., Watabe, I., Savary, E., et al. (2014) HMGA2, the Architectural
666 Transcription Factor High Mobility Group, Is Expressed in the Developing and
667 Mature Mouse Cochlea. *PLOS ONE*, **9**, e88757.
- 668 36. Aleström, P., D’Angelo, L., Midtlyng, P. J., et al. (2019) Zebrafish: Housing and
669 husbandry recommendations. *Lab. Anim.*, 0023677219869037.

- 670 37. Hammond, C. L. and Schulte-Merker, S. (2009) Two populations of endochondral
671 osteoblasts with differential sensitivity to Hedgehog signalling. *Dev. Camb. Engl.*,
672 **136**, 3991–4000.
- 673 38. Parsons, M. J., Pisharath, H., Yusuff, S., et al. (2009) Notch-responsive cells initiate
674 the secondary transition in larval zebrafish pancreas. *Mech. Dev.*, **126**, 898–912.
- 675 39. Thisse, C. and Thisse, B. (2008) High-resolution *in situ* hybridization to whole-
676 mount zebrafish embryos. *Nat. Protoc.*, **3**, 59–69.
- 677 40. Brunt, L. H., Begg, K., Kague, E., et al. (2017) Wnt signalling controls the response
678 to mechanical loading during zebrafish joint development. *Development*, **144**,
679 2798–2809.
- 680 41. Goody, M. F., Kelly, M. W., Reynolds, C. J., et al. (2012) NAD⁺ Biosynthesis
681 Ameliorates a Zebrafish Model of Muscular Dystrophy. *PLoS Biol.*, **10**.
- 682 42. Yushi Yang (2020) yangyushi/FishPy: First release to get a DOI. *yangyushi/FishPy:*
683 *First release to get a DOI*; Zenodo, (2020) .
- 684 43. Ouellette, N. T., Xu, H. and Bodenschatz, E. (2006) A quantitative study of three-
685 dimensional Lagrangian particle tracking algorithms. *Exp. Fluids*, **40**, 301–313.
- 686 44. Xu, H. (2008) Tracking Lagrangian trajectories in position–velocity space. *Meas.*
687 *Sci. Technol.*, **19**, 075105.
- 688 45. Xu, J., Liao, L., Ning, G., et al. (2000) The steroid receptor coactivator SRC-3
689 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty,
690 female reproductive function, and mammary gland development. *Proc. Natl. Acad.*
691 *Sci. U. S. A.*, **97**, 6379–6384.
- 692 46. Louet, J.-F., Coste, A., Amazit, L., et al. (2006) Oncogenic steroid receptor
693 coactivator-3 is a key regulator of the white adipogenic program. *Proc. Natl. Acad.*
694 *Sci. U. S. A.*, **103**, 17868–17873.
- 695 47. York, B., Reineke, E. L., Sagen, J. V., et al. (2012) Ablation of Steroid Receptor
696 Coactivator-3 Resembles the Human CACT Metabolic Myopathy. *Cell Metab.*, **15**,
697 752–763.
- 698 48. Scheffer, D. I., Shen, J., Corey, D. P., et al. (2015) Gene Expression by Mouse Inner
699 Ear Hair Cells during Development. *J. Neurosci.*, **35**, 6366–6380.
- 700 49. Liu, H., Pecka, J. L., Zhang, Q., et al. (2014) Characterization of Transcriptomes of
701 Cochlear Inner and Outer Hair Cells. *J. Neurosci.*, **34**, 11085–11095.
- 702 50. Zhang, B., Li, Z., Wang, W., et al. (2018) NCOA3 Loss Disrupts Molecular
703 Signature of Chondrocytes and Promotes Posttraumatic Osteoarthritis Progression.
704 *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.*, **49**, 2396–
705 2413.
- 706 51. Gee, F., Rushton, M. D., Loughlin, J., et al. (2015) Correlation of the osteoarthritis
707 susceptibility variants that map to chromosome 20q13 with an expression
708 quantitative trait locus operating on NCOA3 and with functional variation at the
709 polymorphism rs116855380. *Arthritis Rheumatol. Hoboken NJ*, **67**, 2923–2932.
- 710 52. Evangelou, E., Kerkhof, H. J., Styrkarsdottir, U., et al. (2014) A meta-analysis of
711 genome-wide association studies identifies novel variants associated with
712 osteoarthritis of the hip. *Ann. Rheum. Dis.*, **73**, 2130–2136.
- 713 53. Sheu, Y.-T., Zmuda, J. M., Cauley, J. A., et al. (2006) Nuclear Receptor
714 Coactivator-3 Alleles Are Associated with Serum Bioavailable Testosterone,
715 Insulin-Like Growth Factor-1, and Vertebral Bone Mass in Men. *J. Clin.*
716 *Endocrinol. Metab.*, **91**, 307–312.
- 717 54. Ao, X., Nie, P., Wu, B., et al. (2016) Decreased expression of microRNA-17 and
718 microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation
719 of NCOA3. *Cell Death Dis.*, **7**, e2463–e2463.

- 720 55. Lundberg, Y. W., Xu, Y., Thiessen, K. D., et al. (2015) Mechanisms of otoconia
721 and otolith development. *Dev. Dyn.*, **244**, 239–253.
- 722 56. Stooke-Vaughan, G. A., Obholzer, N. D., Baxendale, S., et al. (2015) Otolith
723 tethering in the zebrafish otic vesicle requires Otogelin and α -Tectorin.
724 *Development*, **142**, 1137–1145.
- 725 57. Ward, B. K., Tan, G. X.-J., Roberts, D. C., et al. (2014) Strong Static Magnetic
726 Fields Elicit Swimming Behaviors Consistent with Direct Vestibular Stimulation in
727 Adult Zebrafish. *PLOS ONE*, **9**, e92109.
- 728 58. Diaz-Horta, O., Abad, C., Sennaroglu, L., et al. (2016) ROR1 is essential for proper
729 innervation of auditory hair cells and hearing in humans and mice. *Proc. Natl. Acad.
730 Sci.*, **113**, 5993–5998.
- 731 59. Chen, M., Wang, Q., Zhu, G.-H., et al. (2016) Progressive hearing loss and
732 degeneration of hair cell stereocilia in taperin gene knockout mice. *Biochem.
733 Biophys. Res. Commun.*, **479**, 703–707.
- 734 60. Kwon, H.-J. (2016) Vitamin D receptor deficiency impairs inner ear development in
735 zebrafish. *Biochem. Biophys. Res. Commun.*, **478**, 994–998.
- 736 61. Borck, G., Rehman, A. U., Lee, K., et al. (2011) Loss-of-Function Mutations of
737 ILDR1 Cause Autosomal-Recessive Hearing Impairment DFNB42. *Am. J. Hum.
738 Genet.*, **88**, 127–137.
- 739 62. Heeringa, S. F., Chernin, G., Chaki, M., et al. (2011) *COQ6* mutations in human
740 patients produce nephrotic syndrome with sensorineural deafness. *J. Clin. Invest.*,
741 **121**, 2013–2024.
- 742 63. von Ameln, S., Wang, G., Boulouiz, R., et al. (2012) A Mutation in PNPT1,
743 Encoding Mitochondrial-RNA-Import Protein PNPase, Causes Hereditary Hearing
744 Loss. *Am. J. Hum. Genet.*, **91**, 919–927.
- 745 64. Azaiez, H., Decker, A. R., Booth, K. T., et al. (2015) HOMER2, a Stereociliary
746 Scaffolding Protein, Is Essential for Normal Hearing in Humans and Mice. *PLOS
747 Genet.*, **11**, e1005137.
- 748 65. Li, J., Zhao, X., Xin, Q., et al. (2015) Whole-Exome Sequencing Identifies a
749 Variant in TMEM132E Causing Autosomal-Recessive Nonsyndromic Hearing Loss
750 DFNB99. *Hum. Mutat.*, **36**, 98–105.
- 751 66. Dasgupta, S., Lonard, D. M. and O'Malley, B. W. (2014) Nuclear Receptor
752 Coactivators: Master Regulators of Human Health and Disease. *Annu. Rev. Med.*,
753 **65**, 279–292.
- 754 67. Yuan Yuhui, Liao Lan, Tulis David A., et al. (2002) Steroid Receptor Coactivator-3
755 Is Required for Inhibition of Neointima Formation by Estrogen. *Circulation*, **105**,
756 2653–2659.
- 757 68. Xu, J., Shao, Z., Glass, K., et al. (2012) Combinatorial Assembly of Developmental
758 Stage-Specific Enhancers Controls Gene Expression Programs during Human
759 Erythropoiesis. *Dev. Cell*, **23**, 796–811.
- 760 69. Han, S. J., DeMayo, F. J., Xu, J., et al. (2006) Steroid Receptor Coactivator (SRC)-1
761 and SRC-3 Differentially Modulate Tissue-Specific Activation Functions of the
762 Progesterone Receptor. *Mol. Endocrinol.*, **20**, 45–55.
- 763 70. Wang, Z., Shah, O. J. and Hunter, T. (2012) The Transcriptional Coactivators p/CIP
764 and SRC-1 Control Insulin Resistance through IRS1 in Obesity Models. *PLOS
765 ONE*, **7**, e36961.
- 766 71. Wu, Z., Yang, M., Liu, H., et al. (2012) Role of Nuclear Receptor Coactivator 3
767 (Ncoa3) in Pluripotency Maintenance. *J. Biol. Chem.*, **287**, 38295–38304.

- 768 72. York, B., Sagen, J. V., Tsimelzon, A., et al. (2013) Research Resource: Tissue- and
769 Pathway-Specific Metabolomic Profiles of the Steroid Receptor Coactivator (SRC)
770 Family. *Mol. Endocrinol.*, **27**, 366–380.
- 771 73. Coste, A., Louet, J.-F., Lagouge, M., et al. (2008) The genetic ablation of SRC-3
772 protects against obesity and improves insulin sensitivity by reducing the acetylation
773 of PGC-1 α . *Proc. Natl. Acad. Sci.*, **105**, 17187–17192.
- 774 74. Wang, Z., Rose, D. W., Hermanson, O., et al. (2000) Regulation of somatic growth
775 by the p160 coactivator p/CIP. *Proc. Natl. Acad. Sci.*, **97**, 13549–13554.
- 776 75. Nicolson, T. (2005) The Genetics of Hearing and Balance in Zebrafish. *Annu. Rev.*
777 *Genet.*, **39**, 9–22.
- 778 76. Romero-Carvajal, A., Navajas Acedo, J., Jiang, L., et al. (2015) Regeneration of
779 Sensory Hair Cells Requires Localized Interactions between the Notch and Wnt
780 Pathways. *Dev. Cell*, **34**, 267–282.
- 781 77. Haddon, C., Jiang, Y. J., Smithers, L., et al. (1998) Delta-Notch signalling and the
782 patterning of sensory cell differentiation in the zebrafish ear: evidence from the
783 mind bomb mutant. *Development*, **125**, 4637–4644.
- 784 78. Itoh, M. and Chitnis, A. B. (2001) Expression of proneural and neurogenic genes in
785 the zebrafish lateral line primordium correlates with selection of hair cell fate in
786 neuromasts. *Mech. Dev.*, **102**, 263–266.
- 787 79. Andermann, P., Ungos, J. and Raible, D. W. (2002) Neurogenin1 Defines Zebrafish
788 Cranial Sensory Ganglia Precursors. *Dev. Biol.*, **251**, 45–58.
- 789 80. Zhang, B., Li, Z., Wang, W., et al. (2018) NCOA3 Loss Disrupts Molecular
790 Signature of Chondrocytes and Promotes Posttraumatic Osteoarthritis Progression.
791 *Cell. Physiol. Biochem.*, **49**, 2396–2413.
- 792 81. Aşık, M. D., Gürsoy, S., Akkaya, M., et al. (2019) Microarray analysis of cartilage:
793 comparison between damaged and non-weight-bearing healthy cartilage. *Connect.*
794 *Tissue Res.*, **0**, 1–9.
- 795 82. Monsell, E. M. (2004) The Mechanism of Hearing Loss in Paget’s Disease of Bone.
796 *The Laryngoscope*, **114**, 598–606.
- 797 83. Gregson, C. L., Hardcastle, S. A., Cooper, C., et al. (2013) Friend or foe: high bone
798 mineral density on routine bone density scanning, a review of causes and
799 management. *Rheumatol. Oxf. Engl.*, **52**, 968–985.
- 800 84. Han, Y., Mu, Y., Li, X., et al. (2011) Grhl2 deficiency impairs otic development and
801 hearing ability in a zebrafish model of the progressive dominant hearing loss
802 DFNA28. *Hum. Mol. Genet.*, **20**, 3213–3226.
- 803 85. Vona, B., Doll, J., Hofrichter, M. A. H., et al. (2020) Small fish, big prospects:
804 using zebrafish to unravel the mechanisms of hereditary hearing loss. *Hear. Res.*,
805 107906.
- 806 86. Iwasa, Y., Nishio, S., Yoshimura, H., et al. (2013) OTOF mutation screening in
807 Japanese severe to profound recessive hearing loss patients. *BMC Med. Genet.*, **14**,
808 95.
- 809 87. Wagatsuma, M., Kitoh, R., Suzuki, H., et al. (2007) Distribution and frequencies of
810 CDH23 mutations in Japanese patients with non-syndromic hearing loss. *Clin.*
811 *Genet.*, **72**, 339–344.
- 812 88. Ahmed, Z. M., Riazuddin, S., Riazuddin, S., et al. (2003) The molecular genetics of
813 Usher syndrome. *Clin. Genet.*, **63**, 431–444.
- 814 89. Vona, B., Nanda, I., Neuner, C., et al. (2013) Confirmation of GRHL2 as the gene
815 for the DFNA28 locus. *Am. J. Med. Genet. A.*, **161**, 2060–2065.
- 816

817 **Figure Titles and Legends**

818

819 **Figure 1. A rare variant in *NCOA3*, a gene which codes a nuclear receptor**
820 **coactivator, segregates with hearing loss in the family.** A) Pedigree showing the
821 segregation of the *NCOA3* variant (NM_181659: c.2810C>G: p.Ser937Cys). B) 14
822 audiometric profiles (divided in right and left ear) of 7 patients affected with
823 sensorineural and bilateral hearing loss. Hearing thresholds until 20dB are considered
824 normal. C) Chromatograms showing partial sequence from affected patient compared to
825 a wild-type sequence. Arrow indicates position of the *NCOA3* variant, while scale bar
826 below indicates which amino acid is changed when the variant is present. D) Multipoint
827 LOD scores calculated with Merlin software for chromosome 20, using data from SNP
828 arrays, under assumption of complete penetrance $K=1$. E) Schematics of *NCOA3* gene
829 and its respective protein. bHLH= basic helix-loop-helix domain; PAS= Per/ARNT/Sim
830 homologous domain; S/T= serine/threonine-rich region; RID= receptor interaction
831 domain containing multiple LXXLL motifs; AD1 and AD2= activation domains 1 and
832 2. F) Multiple alignment of *NCOA3* gene and its orthologous (left), as well as multiple
833 alignment of the respective proteins (right). Arrow indicates position of *NCOA3* variant
834 (NM_181659: c.2810C>G: p.Ser937Cys).

835 **Figure 2. *Ncoa3* is expressed in mice ear at P4, P10 and P16.** A) RT-PCR shows
836 expression of *Ncoa3* and housekeeping genes *Actb* and *B2m* for the different stages of
837 mice cochlea development and Organ of Corti. M= 100bp molecular weight. Note that
838 *Ncoa3* is expressed in all stages analysed and in both tissue samples. B)
839 Immunofluorescence on transversal histological sections of mice cochlea. In the bottom
840 right corner, a greater zoom of P14 mice cochlea is displayed, showing expression
841 pattern of *NCOA3*. Anti-NCOA3 (red) has been used, with nuclei shown in blue
842 (DAPI). BM= Basilar Membrane, OC= Organ of Corti, RM= Reissner Membrane, SG=

843 Spiral Ganglion, SL= Spiral Limbus, SV= Stria Vascularis, TM= Tectorial Membrane.
844 C) Expression of endogenous *ncoa3* in zebrafish inner ears at larval stages: 3 dpf and
845 5dpf (days post-fertilization); and juvenile stages: 5wpf and 7wpf (weeks-post-
846 fertilization). Scale bars= 200 μ m for 3 and 5 dpf, and 500 μ m for 5 and 7wpf.

847 **Figure 3. Abnormal cartilage behaviour and macula hair distribution in ears of**
848 *ncoa3*^{-/-} A) 3D renders from confocal images of wt and *ncoa3*^{-/-} carrying
849 Tg(*col2:mcherry*, *notch:gfp*) to show cartilage and cristae, respectively. Arrows indicate
850 abnormal cartilage cell behaviour (cell exostosis). (ac= anterior crista, lc= lateral crista,
851 pc= posterior crista). Scale bars= 50 μ m. Regions of anterior crista and macula were
852 zoomed in. Scale bars= 20 μ m. B) Phalloidin staining and confocal imaging to show the
853 distribution of hair cells. Yellow dashed box to show zoomed in region. Abnormal
854 distribution of hair cells was observed in the macula (dashed cyan arrows). Scale bars=
855 50 μ m, zoomed in region = 20 μ m.

856 **Figure 4. Abnormal mineralisation of amorphous material within the adult inner**
857 **ears and higher BMD in *ncoa3*^{-/-}.** A) 3D renders from μ CT images of wt and *ncoa3*^{-/-}
858 of same age (1 year old). The head was color-coded to show bone mineral density
859 (g.cm³HA; min= 0.338; max= 1.124). Note that craniofacial bones in *ncoa3* mutants
860 have higher density compared to wt. Otoliths (otl= arrows) were zoomed in. Abnormal
861 mineralisation (dashed arrows) is observed attached to the otoliths. A cross section
862 picture was taken to show the mineralised amorphous material (arrows) juxtaposed to
863 the otoliths. B) Volume of otoliths. C) Bone mineral density of central region of
864 otoliths. Non-parametric, two-tailed, independent Student's t-Test was used as
865 statistical analysis (p<0.05). Scale bars= 500 μ m.

866 **Figure 5. Altered swimming behaviour of adult *ncoa3*^{-/-} suggests hearing**
867 **malfunction.** A) Overlapped Trajectories of 1-year old wt (n= 7) and *ncoa3*^{-/-} (n= 6).

868 The bottom right corner is shaded, where the fish are more likely to stay. B) Average
869 spatial distribution of wt and *ncoa3*^{-/-}. A brighter colour indicates that the fish are more
870 likely to stay in the respective region. For every trajectory acquired from different fish,
871 the corresponding spatial distribution P(N) was calculated. From every P(N), the
872 standard deviation of N in all the grids is calculated, noted as Std(N). C) Graph of
873 Std(N) values for wt and *ncoa3*^{-/-}. Error bars represent the standard deviation of Std(N).
874 Non-parametric, two tailed, t-Test was used (p =0.06).
875

876 **Tables**

877 Table 1 - Reported ages of onset for hearing loss and ages at the time of clinical
878 examination.

879
880

Patient ID	Classification	Severity of hearing loss	Age at examination (years)	Age of onset (years)
III-5	Affected	Moderate in right ear and severe in the left ear	48	8
III-8	Affected	Profound	40	35
III-10	Affected	Moderate	45	20
IV-6	Affected	Mild	24	7
IV-9	Affected	Mild to severe	22	6
IV-21	Affected	Moderate in right ear and mild in left ear	8	6
IV-22	Affected	Mild	4	4
II-4	Not affected	-	-	-
IV-5	Not affected	Threshold of 35dB only at 6K	27	-
IV-12	Not affected	Threshold of 30dB only at 6K	26	-
IV-15	Not affected	-	20	-
IV-17	Not affected	-	15	-
IV-18	Not affected	Threshold of 28dB only at 6K	11	-
IV-19	Not affected	-	8	-
IV-20	Not affected	-	11	-
V-3	Not affected	-	3	-
V-5	Not affected	-	5	-
V-6	Not affected	-	4	-

881

882

883 Table 2 – Steps of variant filtering after exome sequencing of samples from two
884 affected individuals. *= 66 control samples that were sequenced in the same batch. **=
885 1000 genomes, NHLBI Exome Sequencing Project, Online Archive of Brazilian
886 Mutations databases.
887

Filtration steps of exonic variants	# of remaining variants
Heterozygous variants found in both patients analysed	9197
Exclusion of low-quality variants	9193
Exclusion of variants with f>1% in control-samples*	553
Exclusion of variants with f>1% in databases**	350
Considering only variants in autosomes	349
Exclusion of variants in hypervariable genes	302
Exclusion of synonymous variants	162
Considering only variants in chromosome 20	3
Considering only variants in the positive Lod score region	1

888

889

890 **Abbreviations**

891 Animal Welfare and Ethical Review Body: AWERB

892 Autosomal dominant non-syndromic hearing loss: ADNSHL

893 Bovine serum albumin: BSA

894 Council for International Organizations of Medical Sciences: CIOMS

895 Clustered regularly interspaced short palindromic repeats: CRISPR

896 CRISPR associated protein 9: Cas9

897 Days post fertilization: dpf

898 Ear, nose and throat: ENT

899 European Bioinformatics Institute: EMBL-EBI

900 Genome Aggregation Database: gnomAD

901 Multipoint logarithm of odds: LOD

902 National Heart, Lung, and Blood Institute Exome Sequencing Project: NHLBI-ESP

903 Online Archive of Brazilian Mutations: ABraOM

904 Paraformaldehyde: PFA

905 Postnatal Day: P

906 Wpf: weeks post fertilization

907

Figure 1
 bioRxiv preprint doi: <https://doi.org/10.1101/2020.06.07.138909>; this version posted June 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




Figure 2

bioRxiv preprint doi: <https://doi.org/10.1101/2020.06.07.138909>; this version posted June 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.





Figure 3

bioRxiv preprint doi: <https://doi.org/10.1101/2020.06.07.138909>; this version posted June 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

A



B




Figure 4

bioRxiv preprint doi: <https://doi.org/10.1101/2020.06.07.138909>; this version posted June 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

